awmsg logo



lapatinib (Tyverb®)


Reference No. 1649

Publication date:
13/12/2013


Appraisal information

lapatinib (Tyverb®) 250 mg film-coated tablet


Company: GlaxoSmithKline
BNF category: Malignant disease and immunosupression
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
   
   
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 06/12/2013

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

In the absence of a submission from the holder of the marketing authorisation, lapatinib (Tyverb®) cannot be endorsed for use within NHS Wales for the treatment of patients with breast cancer, whose tumours overexpress HER2 (ErbB2) in combination with trastuzumab for patients with hormone receptor-negative metastatic disease that has progressed on prior trastuzumab therapy(ies) in combination with chemotherapy.
Statement of Advice (SOA)
Download